Genmab — November 2017
-
Genmab announced late yesterday evening after market close that it has received a USD 20m milestone (DKK 125m) from JnJ (Janssen Biotech) based on progress made in the first phase III study in a disease other than multiple myeloma (non-MM). The milestone payment relates to progress in the ongoing phase III ANDROMEDA (AMY3001) study of daratumumab (Darzalex) in combination with cyclophosphamide, bortezomib and dexamethasone in amyloidosis. This is the first late-stage milestone related to ph III
-
progress for Darzalex in a non-MM indication and hence we view it as important and positive news. The milestone is likely triggered by the enrolment and treatment of a certain number of patients in the ph III study, which helps to demonstrate the safety of the drug in this indication. Efficacy-wise, we note that earlier ph II data for Darzalex in amyloidosis have shown extremely impressive responses in this difficult to treat and non-curable disease. Based on the milestone from JnJ, Genmab once
-
again raises guidance for 2017, but this raise is based on milestones (obviously), which are lumpy, and not the underlying performance of Darzalex. Lastly, we note an interesting interview with Genmab’s CEO last night on Bloomberg, with a very bullish tone on Darzalex’s peak sales potential. In the interview, the CEO noted that Darzalex’s future sales are underestimated, including the most positive forecasts of around USD 10bn in peak sales.
-
Hva' satan!? Et FA spørgsmål midt i EI vrøvlet! Bcma er et protein med et chemo-molekule i røven. Car-t er dyrkede antigen celler, der målretter t-cellerne imod tumorer
-
Det er et interessant emne, som Sukkeralf har hintet til mange gange
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind